XOMA is a leader in the discovery, development and manufacture of therapeutic antibodies. XOMA’s exceptionally broad technology platform, leading scientific expertise, and fully integrated product development infrastructure, extends from antibody discovery to regulatory approval. A proven development partner and technology licensor, XOMA receives royalties from Genentech for RAPTIVA® (efalizumab) and LUCENTIS® (ranibizumab injection). Our pipeline includes an expanding number of proprietary products and collaborative programs at various stages of clinical and preclinical development.

Contact Information

2910 Seventh Street
Berkeley, CA 94710

tel: 510-204-7200
fax: 510-644-0539


Investor Relations

Investor Relations and Corporate Communications
Greg Mann
tel: 510-204-7270
e-mail: mann@xoma.com


Exchange: NASDAQ
Industry: Biotechnology
Market Cap: $256.5M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.